{"name":"Zhen-Yu Ding","slug":"zhen-yu-ding","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LG002","genericName":"LG002","slug":"lg002","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"LG002","genericName":"LG002","slug":"lg002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE95bDk0RHlwY3cyOFF2ZzVkNHpRSFREaHNPWEc3VHM2SnhXcjhvMThDekxGYXFYTHpiaWtRbmRyTDJFSUZZOEd4YUZpTC1Jb21SNEhDMlFEaVpyb3NsSVQ0?oc=5","date":"2025-02-19","type":"pipeline","source":"Nature","summary":"Breast cancer: pathogenesis and treatments - Signal Transduction and Targeted Therapy - Nature","headline":"Breast cancer: pathogenesis and treatments - Signal Transduction and Targeted Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9lMmx1XzVRSzhONkdTdzNGSG4zREFDeEVzeFUycW85a25iVW5WYV9uNVo2dVFIeUtJZjRvX3lac3pud1ZhRnEzQ2hZN0o1T3NUc2wtd184UEpQbU5PczBv?oc=5","date":"2024-08-20","type":"trial","source":"Nature","summary":"Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial - Nature","headline":"Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesop","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}